<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01457716</url>
  </required_header>
  <id_info>
    <org_study_id>3103007</org_study_id>
    <nct_id>NCT01457716</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Pilot Study on Budesonide/Formoterol</brief_title>
  <official_title>Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess and compare the Pharmacokinetic (PK) of Budesonide and
      Formoterol after administration of 3 different product variants of Budesonide/Formoterol
      Easyhalers and Symbicort turbuhaler.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Budesonide and Formoterol</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of Budesonide and Formoterol</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Budesonide and Formoterol</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of Budesonide and Formoterol</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Budesonide and Formoterol</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Budesonide/Formoterol Easyhaler A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/Formoterol Easyhaler B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/Formoterol Easyhaler C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/Formoterol Turbohaler Forte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Single inhalation</description>
    <arm_group_label>Budesonide/Formoterol Easyhaler A</arm_group_label>
    <arm_group_label>Budesonide/Formoterol Easyhaler B</arm_group_label>
    <arm_group_label>Budesonide/Formoterol Easyhaler C</arm_group_label>
    <arm_group_label>Budesonide/Formoterol Turbohaler Forte</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Single inhalation</description>
    <arm_group_label>Budesonide/Formoterol Easyhaler A</arm_group_label>
    <arm_group_label>Budesonide/Formoterol Easyhaler B</arm_group_label>
    <arm_group_label>Budesonide/Formoterol Easyhaler C</arm_group_label>
    <arm_group_label>Budesonide/Formoterol Turbohaler Forte</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Easyhaler</intervention_name>
    <description>Inhaler device</description>
    <arm_group_label>Budesonide/Formoterol Easyhaler A</arm_group_label>
    <arm_group_label>Budesonide/Formoterol Easyhaler B</arm_group_label>
    <arm_group_label>Budesonide/Formoterol Easyhaler C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Turbohaler Forte</intervention_name>
    <description>Inhaler device</description>
    <arm_group_label>Budesonide/Formoterol Turbohaler Forte</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females, 18-55 years of age.

          -  Normal weight at least 50 kg.

        Exclusion Criteria:

          -  Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,
             gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease.

          -  Any condition requiring concomitant treatment (including vitamins and herbal
             products)or likely to need any concomitant treatment during the study

          -  Any clinically significant abnormal laboratory value or physical finding that may
             interfere with the interpretation of test results or cause a health risk for the
             subject if he/she participates in the study.

          -  Known hypersensitivity to the active substance(s) or to any of the excipients of the
             drug.

          -  Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Hietam√§ki, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

